CellVax Therapeutics Doses First Patient in Phase 2 Trial of Personalized Immunotherapy FK-PC101 for Prostate Cancer
• CellVax Therapeutics has dosed the first patient in a Phase 2 clinical trial of FK-PC101, a personalized immunotherapy for prostate cancer.
• FK-PC101 utilizes the patient's own modified tumor cells to stimulate an immune response against recurrent prostate cancer.
• The Phase 2 trial (CELLVX-230) is a multicenter, adaptive, randomized, open-label study in men with high-risk prostate cancer post-prostatectomy.
• Theragent is responsible for the end-to-end manufacturing, release, and disposition of FK-PC101 clinical material.
First Patient Dosed in Phase 2 Trial of Personalized Prostate Cancer Immunotherapy FK-PC101
• Theragent and CellVax Therapeutics announced the first patient has been dosed in a Phase 2 clinical trial of FK-PC101, a personalized cancer immunotherapy.
• FK-PC101 is designed to treat prostate cancer patients at high risk of recurrence following prostatectomy by utilizing modified autologous tumor cells.
• The Phase 2 trial (CELLVX-230) is a multicenter, adaptive, randomized, open-label study conducted in partnership with the Society of Urologic Oncology Clinical Trials Consortium.
• FK-PC101 aims to delay or prevent the need for salvage radiotherapy and/or androgen deprivation therapy, which can negatively impact patients' quality of life.
© Copyright 2025. All Rights Reserved by MedPath